Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers

Journal of Virology

Volumn 77, Issue 9, 2003, Pages 5226-5240

  Elkington, Rebecca ^b   Walker, Susan ^b   Crough, Tania ^b   Menzies, Moira ^b   Tellam, Judy ^b   Bharadwaj, Mandvi ^b   Khanna, Rajiv ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; PEPTIDE; STRUCTURAL PROTEIN; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; BIOINFORMATICS; CELL ASSAY; CELLULAR IMMUNITY; HLA SYSTEM; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNOGENICITY; IN VIVO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RESTRICTION MAPPING; T LYMPHOCYTE; VIRUS CARRIER; VIRUS INTERFERENCE; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANTIGENS, VIRAL; CARRIER STATE; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; COMPUTATIONAL BIOLOGY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; EPITOPE MAPPING; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 0345373932     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.9.5226-5240.2003     Document Type: Article

References (53)

1. Adler, S. P., K. V. Shaw, M. McVoy, R. L. Burke, and H. Liu. 1995. Guinea pig and human cytomegaloviruses do not share cross-reactive neutralizing epitopes. J. Med. Virol. 47:48-51.
2. Akiyama, Y., K. Maruyama, T. Mochizuki, K. Sasaki, Y. Takaue, and K. Yamaguchi. 2002. Identification of HLA-A24-restricted CTL epitope encoded by the matrix protein pp65 of human cytomegalovirus. Immunol. Lett. 83:21-30.
3. Alford, C. A., S. Stagno, R. F. Pass, and W. J. Britt. 1990. Congenital and perinatal cytomegalovirus infections. Rev. Infect. Dis. 12(Suppl. 7):S745-S753.
4. Bharadwaj, M., M. Sherritt, R. Khanna, and D. J. Moss. 2001. Contrasting Epstein-Barr virus-specific cytotoxic T cell responses to HLA A2-restricted epitopes in humans and HLA transgenic mice: implications for vaccine design. Vaccine 19:3769-3777.
5. Blake, N., T. Haigh, G. Shaka'a, D. Croom-Carter, and A. Rickinson. 2000. The importance of exogenous antigen in priming the human CD8+ T cell response: lessons from the EBV nuclear antigen EBNA1. J. Immunol. 165:7078-7087.
6. Blake, N., S. Lee, I. Redchenko, W. Thomas, N. Steven, A. Leese, P. Steigerwald-Mullen, M. G. Kurilla, L. Frappier, and A. Rickinson. 1997. Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 7:791-802.
7. Borysiewicz, L. K., J. K. Hickling, S. Graham, J. Sinclair, M. P. Cranage, G. L. Smith, and J. G. Sissons. 1988. Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J. Exp. Med. 168:919-931.
8. Britt, W. J., and M. Mach. 1996. Human cytomegalovirus glycoproteins. Intervirology 39:401-412.
9. Britt, W. J., L. Vugler, E. J. Butfiloski, and E. B. Stephens. 1990. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J. Virol. 64:1079-1085.
10. Browne, H., G. Smith, S. Beck, and T. Minson. 1990. A complex between the MHC class I homologue encoded by human cytomegalovirus and beta 2 microglobulin. Nature 347:770-772.
11. Burrows, J. M., R. Khanna, T. B. Sculley, M. P. Alpers, D. J. Moss, and S. R. Burrows. 1996. Identification of a naturally occurring recombinant Epstein-Barr virus isolate from New Guinea that encodes both type 1 and type 2 nuclear antigen sequences. J. Virol. 70:4829-4833.
12. Burrows, S. R., S. J. Rodda, A. Suhrbier, H. M. Geysen, and D. J. Moss. 1992. The specificity of recognition of a cytotoxic T lymphocyte epitope. Eur. J. Immunol. 22:191-195.
13. Chevalier, M. S., G. M. Daniels, and D. C. Johnson. 2002. Binding of human cytomegalovirus US2 to major histocompatibility complex class I and II proteins is not sufficient for their degradation. J. Virol. 76:8265-8275.
14. Diamond, D. J., J. York, J. Y. Sun, C. L. Wright, and S. J. Forman. 1997. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 90:1751-1767.
15. Fowler, K. B., S. Stagno, R. F. Pass, W. J. Britt, T. J. Boll, and C. A. Alford. 1992. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N. Engl. J. Med. 326:663-667.
16. Frankenberg, N., S. Pepperl-Klindworth, R. G. Meyer, and B. Plachter. 2002. Identification of a conserved HLA-A2-restricted decapeptide from the IE1 protein (pUL123) of human cytomegalovirus. Virology 295:208-216.
17. Gonczol, E., and S. Plotkin. 2001. Development of a cytomegalovirus vaccine: lessons from recent clinical trials. Expert. Opin. Biol. Ther. 1:401-412.
18. Gyulai, Z., V. Endresz, K. Burian, S. Pincus, J. Toldy, W. I. Cox, C. Meric, S. Plotkin, E. Gonczol, and K. Berencsi. 2000. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs. J. Infect. Dis. 181:1537-1546.
19. Kern, F., T. Bunde, N. Faulhaber, F. Kiecker, E. Khatamzas, I. M. Rudawski, A. Pruss, J. W. Gratama, R. Volkmer-Engert, R. Ewert, P. Reinke, H. D. Volk, and L. J. Picker. 2002. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J. Infect. Dis. 185:1709-1716.
20. Kern, F., N. Faulhaber, E. Khatamzas, C. Frommel, R. Ewert, S. Prosch, H. Volk, and P. Reinke. 1999. Measurement of anti-human cytomegalovirus T cell reactivity in transplant recipients and its potential clinical use: a minireview. Intervirology 42:322-324.
21. Khanna, R., S. R. Burrows, M. G. Kurilla, C. A. Jacob, I. S. Misko, T. B. Sculley, E. Kieff, and D. J. Moss. 1992. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J. Exp. Med. 176:169-176.
22. Khanna, R., C. A. Jacob, S. R. Burrows, M. G. Kurilla, E. Kieff, I. S. Misko, T. B. Sculley, and D. J. Moss. 1991. Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T cells. Immunology 74:504-510.
23. Khanna, R., C. A. Jacob, S. R. Burrows, and D. J. Moss. 1993. Presentation of endogenous viral peptide epitopes by anti-CD40 stimulated human B cells following recombinant vaccinia infection. J. Immunol. Methods 164:41-49.
24. Khanna, R., S. L. Silins, Z. Weng, D. Gatchell, S. R. Burrows, and L. Cooper. 1999. Cytotoxic T cell recognition of allelic variants of HLA B35 bound to an Epstein-Barr virus epitope: influence of peptide conformation and TCR-peptide interaction. Eur. J. Immunol. 29:1587-1597.
25. Kuzushima, K., N. Hayashi, H. Kimura, and T. Tsurumi. 2001. Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood 98:1872-1881.
26. Masuoka, M., T. Yoshimuta, M. Hamada, M. Okamoto, T. Fumimori, J. Honda, K. Oizumi, and K. Itoh. 2001. Identification of the HLA-A24 peptide epitope within cytomegalovirus protein pp65 recognized by CMV-specific cytotoxic T lymphocytes. Viral Immunol. 14:369-377.
27. Mocarski, E. S., and C. T. Courcelle. 2001, Cytomegaloviruses and their replication, p. 2629-2673. In D. M. Knipe and P. M. Howley (ed.), Fields virology. Lippincott Williams & Wilkins, Philadelphia, Pa.
28. Moss, D. J., I. S. Misko, S. R. Burrows, K. Burman, R. McCarthy, and T. B. Sculley. 1988. Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants. Nature 331:719-721.
29. Parker, K. C., M. A. Bednarek, and J. E. Coligan. 1994. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152:163-175.
30. Pass, R. F. 2001. Cytomegalovirus, p. 2675-2705. In D. M. Knipe and P. M. Howley (ed.), Fields virology. Lippincott Williams & Wilkins, Philadelphia, Pa.
31. Plotkin, S. A. 1999. Conclusions. Am. Heart J. 138:S560.
32. Plotkin, S. A. 1999. Vaccination against cytomegalovirus the changeling demon. Pediatr. Infect. Dis. J. 18:313-325.
33. Plotkin, S. A., S. E. Starr, H. M. Friedman, E. Gonczol, and K. Brayman. 1990. Vaccines for the prevention of human cytomegalovirus infection. Rev. Infect. Dis. 12(Suppl. 7):S827-S838.
34. Rammensee, H., J. Bachmann, N. P. Emmerich, O. A. Bachor, and S. Stevanovic. 1999. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213-219.
35. Reddehase, M. J. 2000. The immunogenicity of human and murine cytomegaloviruses. Curr. Opin. Immunol. 12:390-396.
36. Reddehase, M. J. 2002. Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat. Rev. Immunol. 2:831-844.
37. Retiere, C., V. Prod'homme, B. M. Imbert-Marcille, M. Bonneville, H. Vie, and M. M. Hallet. 2000. Generation of cytomegalovirus-specific human T-lymphocyte clones by using autologous B-lymphoblastoid cells with stable expression of pp65 or IE1 proteins: a tool to study the fine specificity of the antiviral response. J. Virol. 74:3948-3952.
38. Riddell, S. R., and P. D. Greenberg. 1997. T cell therapy of human CMV and EBV infection in immunocompromised hosts. Rev. Med. Virol. 7:181-192.
39. Riddell, S. R., P. Reusser, and P. D. Greenberg. 1991. Cytotoxic T cells specific for cytomegalovirus: a potential therapy for immunocompromised patients. Rev. Infect. Dis. 13(Suppl. 11):S966-S973.
40. Salter, R. D., and P. Cresswell. 1986. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. EMBO J. 5:943-949.
41. Saulquin, X., C. Ibisch, M. A. Peyrat, E. Scotet, M. Hourmant, H. Vie, M. Bonneville, and E. Houssaint. 2000. A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirus by bulk screening. Eur. J. Immunol. 30:2531-2539.
42. Scholz, M., H. W. Doerr, and J. Cinati. 2001. Inhibition of cytomegalovirus immediate early gene expression: a therapeutic option? Antivir. Res. 49:129-145.
43. Sissons, J. G. 1986. The immunology of cytomegalovirus infection. J. R. Coll. Physicians Lond. 20:40-44.
44. Smith, K. D., and C. T. Lutz. 1996. Peptide-dependent expression of HLA-B7 on antigen processing-deficient T2 cells. J. Immunol. 156:3755-3764.
45. Sweet, C. 1999. The pathogenicity of cytomegalovirus. FEMS Microbiol. Rev. 23:457-482.
46. Takiguchi, M., G. Kawaguchi, M. Sekimata, M. Hiraiwa, A. Kariyone, and Y. Takamiya. 1994. The role of the conserved residue in pocket A and the polymorphic residue in pocket E of HLA-B*3501 in presentation of human minor histocompatibility peptides to T cells. Int. Immunol. 6:1345-1352.
47. Thimme, R., D. Oldach, K. M. Chang, C. Steiger, S. C. Ray, and F. V. Chisari. 2001. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 194:1395-1406.
48. Thomson, S. A., R. Khanna, J. Gardner, S. R. Burrows, B. Coupar, D. J. Moss, and A. Suhrbier. 1995. Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design. Proc. Natl. Acad. Sci. USA 92:5845-5849.
49. Valerio, R. M., M. Benstead, A. M. Bray, R. A. Campbell, and N. J. Maeji. 1991. Synthesis of peptide analogues using the multipin peptide synthesis method. Anal. Biochem. 197:168-177.
50. Weekes, M. P., M. R. Wills, K. Mynard, A.J. Carmichael, and J. G. Sissons. 1999. The memory cytotoxic T-lymphocyte (CTL) response to human cytomegalovirus infection contains individual peptide-specific CTL clones that have undergone extensive expansion in vivo. J. Virol. 73:2099-2108.
51. Wills, M. R., A. J. Carmichael, K. Mynard, X. Jin, M. P. Weekes, B. Plachter, and J. G. Sissons. 1996. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J. Virol. 70:7569-7579.
52. Zaia, J. A., J. G. Sissons, S. Riddell, D. J. Diamond, M. R. Wills, A. J. Carmichael, M. P. Weekes, M. Gandhi, C. L. Rosa, M. Villacres, S. Lacey, S. Markel, and J. Sun. 2000. Status of cytomegalovirus prevention and treatment in 2000. Hematol.(Am. Soc. Hematol. Educ. Program) 2000:339-355.
53. Zweerink, H. J., M. C. Gammon, U. Utz, S. Y. Sauma, T. Harrer, J. C. Hawkins, R. P. Johnson, A. Sirotina, J. D. Hermes, and B. D. Walker. 1993. Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells. J. Immunol. 150:1763-1771.